02029nam a2200385 i 4500001001300000003000300013005001700016006001900033007001500052008004100067040003900108042000800147043001200155050002100167074002000188086002900208110014500237245031000382264006000692300005600752336002600808337002600834338003600860490002300896500010800919500002501027504004101052588011901093650004201212650004101254655003301295776021701328810006001545856003801605ocn988946299BD20180426225221.0m     o  d f      cr bn||||a||||170605s2017    dcua    ob   f000 0 eng c  aPUCPRbengerdaepncGPOdGPOdMvI  apcc  an-us---14aKF26b.L277 2014  a1043-C (online)0 aY 4.L 11/4:S.HRG.113-8591 aUnited States.bCongress.bSenate.bCommittee on Health, Education, Labor, and Pensions.bSubcommittee on Primary Health and Aging,eauthor.10aWhy are some generic drugs skyrocketing in price? :bhearing before the Subcommittee on Primary Health and Aging of the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Thirteenth Congress, second session, on examining the pricing of generic drugs, November 20, 2014. 1aWashington :bU.S. Government Publishing Office,c2017.  a1 online resource (iii, 65 pages) :billustrations.  atextbtxt2rdacontent  acomputerbc2rdamedia  aonline resourcebcr2rdacarrier1 aS. hrg. ;v113-859  aPaper version available for sale by the Superintendent of Documents, U.S. Government Publishing Office.  aCRDP Program record.  aIncludes bibliographical references.  aDescription based on online resource, PDF version; title from title page (FDsys web site, viewed on June 5, 2017). 0aGeneric drugsxPriceszUnited States. 0aPrescription pricingzUnited States. 7aLegislative hearings.2lcgft08iPrint version:aUnited States. Congress. Senate. Committee on Health, Education, Labor, and Pensions. Subcommittee on Primary Health and Aging.tWhy are some generic drugs skyrocketing in price?w(OCoLC)9897298131 aUnited States.bCongress.bSenate.tS. hrg. ;v113-859.40uhttp://purl.fdlp.gov/GPO/gpo81355